These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26914555)

  • 1. Utility of FDG PET/CT for Differential Diagnosis of Patients Clinically Suspected of IgG4-Related Disease.
    Lee J; Hyun SH; Kim S; Kim DK; Lee JK; Moon SH; Cho YS; Choe YS; Kim BT; Lee KH
    Clin Nucl Med; 2016 May; 41(5):e237-43. PubMed ID: 26914555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases.
    Zhao Z; Wang Y; Guan Z; Jin J; Huang F; Zhu J
    Clin Exp Rheumatol; 2016; 34(1):119-25. PubMed ID: 26842851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of
    Takano K; Yajima R; Kamekura R; Yamamoto M; Takahashi H; Yama N; Hatakenaka M; Himi T
    Laryngoscope; 2018 May; 128(5):1120-1125. PubMed ID: 28988418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of F-18 FDG PET/CT in assessing IgG4-related disease with inflammation of head and neck glands.
    Tokue A; Higuchi T; Arisaka Y; Nakajima T; Tokue H; Tsushima Y
    Ann Nucl Med; 2015 Jul; 29(6):499-505. PubMed ID: 25877159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of FDG-PET/CT and other imaging techniques in the evaluation of IgG4-related disease.
    Takahashi H; Yamashita H; Morooka M; Kubota K; Takahashi Y; Kaneko H; Kano T; Mimori A
    Joint Bone Spine; 2014 Jul; 81(4):331-6. PubMed ID: 24568886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing IgG4-related disease with ¹⁸F-FDG PET/CT: a prospective cohort study.
    Zhang J; Chen H; Ma Y; Xiao Y; Niu N; Lin W; Wang X; Liang Z; Zhang F; Li F; Zhang W; Zhu Z
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1624-34. PubMed ID: 24764034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of
    Bai Z; Zhou T; Yu Z; Chen Y; Dong L
    Ann Nucl Med; 2022 Jul; 36(7):651-660. PubMed ID: 35604531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study.
    Ebbo M; Grados A; Guedj E; Gobert D; Colavolpe C; Zaidan M; Masseau A; Bernard F; Berthelot JM; Morel N; Lifermann F; Palat S; Haroche J; Mariette X; Godeau B; Bernit E; Costedoat-Chalumeau N; Papo T; Hamidou M; Harlé JR; Schleinitz N
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):86-96. PubMed ID: 23836437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the features of fluorine-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) between IgG4-related disease with bilateral hilar lymphadenopathy and sarcoidosis.
    Ozawa Y; Yamamoto H; Yasuo M; Komatsu M; Ushiki A; Hamano H; Uehara T; Kawakami S; Fujita A; Fujinaga Y; Oguchi K; Kawa S; Hanaoka M
    Nagoya J Med Sci; 2020 Feb; 82(1):101-111. PubMed ID: 32273638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease.
    Berti A; Della-Torre E; Gallivanone F; Canevari C; Milani R; Lanzillotta M; Campochiaro C; Ramirez GA; Bozzalla Cassione E; Bozzolo E; Pedica F; Castiglioni I; Arcidiacono PG; Balzano G; Falconi M; Gianolli L; Dagna L
    Rheumatology (Oxford); 2017 Dec; 56(12):2084-2092. PubMed ID: 28977663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
    Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
    Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the quantitative measurement of 18F-FDG PET/CT and histopathological findings in IgG4-related disease.
    Tsuji S; Iwamoto N; Horai Y; Fujikawa K; Fujita Y; Fukui S; Ideguchi R; Michitsuji T; Nishihata S; Okamoto M; Tsuji Y; Endo Y; Shimizu T; Sumiyoshi R; Koga T; Kawashiri SY; Igawa T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kudo T; Kawakami A
    Clin Exp Rheumatol; 2021; 39(6):1338-1344. PubMed ID: 33506750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG4-Related Disease Simulating Carcinoma Colon With Diffuse Peritoneal Carcinomatosis on 18F-FDG PET/CT.
    Vadi SK; Parihar AS; Kumar R; Singh H; Mittal BR; Bal A; Sinha SK
    Clin Nucl Med; 2018 Jul; 43(7):e247-e249. PubMed ID: 29762245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of imaging modalities for screening IgG4-related dacryoadenitis and sialadenitis (Mikulicz's disease) and for differentiating it from Sjögren's syndrome (SS), with an emphasis on sonography.
    Shimizu M; Okamura K; Kise Y; Takeshita Y; Furuhashi H; Weerawanich W; Moriyama M; Ohyama Y; Furukawa S; Nakamura S; Yoshiura K
    Arthritis Res Ther; 2015 Aug; 17(1):223. PubMed ID: 26298875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.
    Shiiba M; Ishihara K; Kimura G; Kuwako T; Yoshihara H; Sato H; Kondo Y; Tsuchiya S; Kumita S
    Ann Nucl Med; 2012 Feb; 26(2):138-45. PubMed ID: 22069194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total lesion glycolysis as an IgG4-related disease activity marker.
    Nakatsuka Y; Handa T; Nakamoto Y; Nobashi T; Yoshihuji H; Tanizawa K; Ikezoe K; Sokai A; Kubo T; Hirai T; Chin K; Togashi K; Mimori T; Mishima M
    Mod Rheumatol; 2015 Jul; 25(4):579-84. PubMed ID: 25437196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
    Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
    Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.